Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 6/2008

01-06-2008 | Letter to the editor

Antibody to a high-prevalence blood group antigen Ata associated with Sjögren’s syndrome

Authors: Siddharth Mathur, Harwinder Sawhney, Maud A. Bertoni, Renuka Gupta

Published in: Annals of Hematology | Issue 6/2008

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Applewhaite F, Ginsburg V, Cunningham CA, Gavin J (1967) A very frequent red cell antigen Ata. Vox Sang 13:444–445PubMedCrossRef
2.
Sweeney JD, Holmes S, McCall L et al (1995) At(a-) phenotype: description of a family and reduced survival of At(a+) red cells in proposita with anti-Ata. Transfusion 35:63–67PubMedCrossRef
3.
Winkler MM, Hamilton JR (1990) Previously tested donors eliminated to determine rare phenotype frequencies, abstract. Joint congress of International Society of Blood Transfusion and American association of Blood Banks. AABB, Arlington, p p 158
4.
Ramsey G, Sherman LA, Zimmer AM et al (1995) Clinical significance of anti-Ata. Vox Sang 69:135–137PubMed
5.
Cash KL, Brown T, Sausais L et al (1999) Severe delayed hemolytic transfusion reaction secondary to anti-Ata. Transfusion 39:834–837PubMedCrossRef
6.
Woodfield G, Poole J, Nance ST, Daniels G (2004) A review of the ISBT rare blood donor program. Immunohematology 20:244–248PubMed
Metadata
Title
Antibody to a high-prevalence blood group antigen Ata associated with Sjögren’s syndrome
Authors
Siddharth Mathur
Harwinder Sawhney
Maud A. Bertoni
Renuka Gupta
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 6/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-007-0419-y

Other articles of this Issue 6/2008

Annals of Hematology 6/2008 Go to the issue

Original Article

Haemoglobin Hokusetsu [β52 (D3)] Asp→Gly in German families associated with inclusion body

Review Article

Simultaneous expression of Oct4 and genes of three germ layers in single cell-derived multipotent adult progenitor cells

Letter to the Editor

Mast cell leukemia: a report of ten cases

Letter to the Editor

High-dose melphalan followed by a second bone marrow transplantation in early relapse of acute myeloid leukemia after bone marrow transplantation in children

Letter to the Editor

Vinorelbine and gemcitabine as salvage treatment in advanced and very poor prognosis non-Hodgkin’s lymphoma patients

Letter to the Editor

Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits